TY - JOUR
T1 - Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin
AU - Garbutcheon-Singh, K. Benjamin
AU - Harper, Benjamin W. J.
AU - Myers, Simon
AU - Aldrich-Wright, Janice R.
PY - 2014
Y1 - 2014
N2 - With current chemotherapeutic treatment regimes often limited by adverse side effects, the synergistic combination of complexes with anticancer activity appears to offer a promising strategy for effective cancer treatment. This work investigates the anti-proliferative activity using a combination therapy approach where metallointercalators of the type [Pt(IL)(AL)]2+ (where IL is the intercalating ligand and AL is the ancillary ligand) are used in combination with currently approved anticancer drugs cisplatin and carboplatin and organic molecules buthionine-S,R-sulfoximine and 3-bromopyruvate. Synergistic relationships were observed, indicating a potential to decrease dose-dependent toxicity and improve therapeutic efficacy.
AB - With current chemotherapeutic treatment regimes often limited by adverse side effects, the synergistic combination of complexes with anticancer activity appears to offer a promising strategy for effective cancer treatment. This work investigates the anti-proliferative activity using a combination therapy approach where metallointercalators of the type [Pt(IL)(AL)]2+ (where IL is the intercalating ligand and AL is the ancillary ligand) are used in combination with currently approved anticancer drugs cisplatin and carboplatin and organic molecules buthionine-S,R-sulfoximine and 3-bromopyruvate. Synergistic relationships were observed, indicating a potential to decrease dose-dependent toxicity and improve therapeutic efficacy.
UR - http://handle.uws.edu.au:8081/1959.7/539110
U2 - 10.1039/c3mt00191a
DO - 10.1039/c3mt00191a
M3 - Article
SN - 1756-5901
VL - 6
SP - 126
EP - 131
JO - Metallomics
JF - Metallomics
IS - 1
ER -